Organon (OGN) Appoints Ramona A. Sequeira to its Board
FREE Breaking News Alerts from StreetInsider.com!
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Tech selloff weighs down Wall Street as bond yields climb
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors
April 15, 2025 5:00 PM EDTJERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN) a global healthcare company with a focus on womens health, today announced the appointment of Ramona A. Sequeira, President of the Global Portfolio Division at Takeda Pharmaceutical Company, to Organons Board of Directors, effective July 1, 2025. Ms. Sequeira will serve on the Boards Talent Committee. In connection with Ms. Sequeiras appointment, the size of Organons Board will be expanded to 12 directors.
Ms. Sequeira brings more than 30 years of pharmaceutical industry expertise, with 20 years at Eli Lilly and Company... More
